Clinical Cancer Research Targets Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Janssen, A. M. L.
Right arrow Articles by Verspaget, H. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Janssen, A. M. L.
Right arrow Articles by Verspaget, H. W.
Clinical Cancer Research Vol. 8, 1889-1896, June 2002
© 2002 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Prognostic Significance of Metallothionein in Human Gastrointestinal Cancer1

A. Miranda L. Janssen, Wim van Duijn, Frank J. G. M. Kubben, Gerrit Griffioen, Cornelis B. H. W. Lamers, Johan H. J. M. van Krieken2, Cornelis J. H. van de Velde and Hein W. Verspaget3

Departments of Gastroenterology and Hepatology [A. M. L. J., W. v. D., F. J. G. M. K., G. G., C. B. H. W. L., H. W. V.], Pathology [J. H. J. M. v. K.], and Oncologic Surgery [C. J. H. v. d. V.], Leiden University Medical Center, 2300 RC Leiden, the Netherlands

Purpose: Metallothionein (MT) is a small protein with a high affinity for divalent heavy metal ions. This metalloproteinis involved in many (patho)physiological processes, like metal homeostasis and detoxification, cell proliferation, apoptosis, therapy resistance, and protection against oxidative damage. Alterations in the immunohistochemical expression of MT have been reported for various human tumors, and a high expression has been found to be associated with a poor clinical outcome. We showed previously that gastrointestinal cancer is accompanied by a decrease in MT expression, but the most malignant phenotypes had the highest MT levels. The purpose of the present study was to assess the clinical relevance of MT in gastrointestinal cancer.

Experimental Design: In this study, we determined the MT levels, by radioimmunoassay, in intestinal tissue of 251 patients with colorectal cancer and 81 patients with gastric cancer and assessed the relation with the overall survival of these patients.

Results: More than 74% of the carcinomas were found to have a lower MT level than their corresponding normal mucosa. In colorectal cancer patients, but not in gastric cancer patients, a high MT level in both the carcinomas and normal mucosa was, however, significantly associated with a poor overall survival, independently from clinicopathological features.

Conclusions: Overexpression of MT in intestinal tissue of colorectal cancer patients is a prognostic marker for a poor overall survival. In gastric cancer, however, MT expression in the gastric mucosa is not of prognostic significance. This observation emphasizes the clinical relevance of this multifunctional metalloprotein in colorectal carcinogenesis and therapy.




This article has been cited by other articles:


Home page
BioinformaticsHome page
J. K. Choi, U. Yu, O. J. Yoo, and S. Kim
Differential coexpression analysis using microarray data and its application to human cancer
Bioinformatics, December 15, 2005; 21(24): 4348 - 4355.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
R. Shimoda, W. E. Achanzar, W. Qu, T. Nagamine, H. Takagi, M. Mori, and M. P. Waalkes
Metallothionein Is a Potential Negative Regulator of Apoptosis
Toxicol. Sci., June 1, 2003; 73(2): 294 - 300.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Hernan, R. Fasheh, C. Calabrese, A. J. Frank, K. H. Maclean, D. Allard, R. Barraclough, and R. J. Gilbertson
ERBB2 Up-Regulates S100A4 and Several other Prometastatic Genes in Medulloblastoma
Cancer Res., January 1, 2003; 63(1): 140 - 148.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.